Rahul Aggarwal

MD

Developmental therapeutics specialist
Genitourinary oncologist
Cancer researcher and sports enthusiast

Dr. Rahul Aggarwal is a specialist in cancers of the genital and urinary organs. He cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center. He also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men who are receiving androgen deprivation therapy, hormone therapy for prostate cancer.

As a member of the Developmental Therapeutics Genitourinary Cancer Program, Aggarwal enrolls patients with advanced solid tumor malignancies into early-phase clinical trials of novel targeted treatments. His research focuses on developing hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer. He is also interested in developing new molecular imaging techniques that will help predict how advanced solid tumors will respond to treatment.

Aggarwal earned his medical degree from the Northwestern University Feinberg School of Medicine. At UCSF, he completed an internship and residency in internal medicine, followed by a clinical fellowship in hematology and oncology.

Aggarwal has also been a research fellow in developmental therapeutics at Genentech. He is a member of the American Society of Clinical Oncology (ASCO) and recipient of the ASCO/Conquer Cancer Foundation Young Investigator Award.

  • Education

    Northwestern University Feinberg School of Medicine, 2006

  • Residencies

    UCSF Medical Center, Internal Medicine, 2009

  • Fellowships

    UCSF Medical Center, Hematology/Oncology, 2013

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

    Hematology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

It's an honor to help take care of people with cancer, and I strive each and every day to improve outcomes for our patients.

Conditions I specialize in

Where I see patients (4)

    My reviews

    5.0

    Overall Experience
    492 Ratings
    Explained things in a way that was easy to understand
    489 Ratings
    Did the doctor pay attention to your concerns
    489 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    480 Ratings
    Knew the important information about your medical history
    487 Ratings
    The provider showed respect for what you had to say
    485 Ratings
    The provider spent enough time with me
    490 Ratings
    Read all reviews About our process

    Selected research

    See all research
    Decorative Caduceus

    FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostat...

    A minimum of 3 patients will be treated at each dose level. If < 33%of patients (i.e. 0 of 3 patients, or 1 of 6 patients) within a cohort have a dose-limiting toxicity (DLT in Cycle 1, then enrollment of the next cohort may comme...

    Recruiting

    Decorative Caduceus

    APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation ...

    Adverse events, serious adverse events, and dose limiting toxicities

    Recruiting

    Decorative Caduceus

    Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prost...

    The composite response rate is determined by a combination of a decline from baseline in serum PSA of >= 50%, confirmed by repeat measurement ≥ 4 weeks later (PSA50) AND/OR a complete response (CR) or partial response (PR) as dete...

    Recruiting

    Decorative Caduceus

    A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer

    Recruiting

    Decorative Caduceus

    ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...

    Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...

    Recruiting

    Decorative Caduceus

    Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With C...

    The primary endpoint for the study is the proportion of patients with undetectable serum PSA (< 0.2 ng/mL) at 6 months following completion of apalutamide therapy (18 months from date of randomization). Patients who discontinue ap...

    Recruiting

    Decorative Caduceus

    68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

    The mean SUVmax and standard deviation across the primary tumor and the 5 largest lesions in each of three metastatic sites (nodal, visceral and osseous; for a maximum of 16 lesions per patient) will be descriptively reported.

    Recruiting

    Decorative Caduceus

    A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

    To determine the maximum tolerated dose (MTD) and/or recommended dose (RD) for further evaluation of XL092 when administered alone and in combination with immune checkpoint inhibitors (ICIs) to subjects with advanced solid tumors

    Recruiting

    Decorative Caduceus

    Phase II Trial of AZD6738 Alone and in Combination With Olaparib

    ORR will be measured using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and Will be based on one-sided exact binomial test comparison of the observed ORR in evaluable patients to the null-hypothesized valu...

    Recruiting

    Decorative Caduceus

    Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

    First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug

    Recruiting

    Contact me

    Providers on my team

    Share